Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand.
Michael M PageElif I EkinciJohn R BurnettAmanda J HooperNicola ReidWarrick BishopChris M FlorkowskiRussell ScottRichard C O'BrienGerald F WattsPublished in: Journal of clinical apheresis (2020)
While PCSK9 inhibitors have reduced the need for LA, some patients with severe FH continue to require LA, and will require it for the foreseeable future. However, emerging therapies, including angiopoetin-like 3 inhibitors, may further reduce the need for LA.